Isoproterenol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Isoproterenol
| |
| Systematic (IUPAC) name | |
| 4-[1-hydroxy-2-(1-methylethylamino) ethyl] benzene-1,2-diol | |
| Identifiers | |
| CAS number | |
| ATC code | C01 R03AB02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H17NO3 |
| Mol. mass | 211.258 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | inhaled 80-120μg |
|
WikiDoc Resources for Isoproterenol | |
|
Articles | |
|---|---|
|
Most recent articles on Isoproterenol Most cited articles on Isoproterenol | |
|
Media | |
|
Powerpoint slides on Isoproterenol | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Isoproterenol at Clinical Trials.gov Trial results on Isoproterenol Clinical Trials on Isoproterenol at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Isoproterenol NICE Guidance on Isoproterenol
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Isoproterenol Discussion groups on Isoproterenol Patient Handouts on Isoproterenol Directions to Hospitals Treating Isoproterenol Risk calculators and risk factors for Isoproterenol
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Isoproterenol | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Isoproterenol hydrochloride or isoprenaline (Medihaler-Iso®) is a sympathomimetic beta adrenergic receptor agonist medication.
It is structurally similar to epinephrine but acts for the most part on beta receptors.
Uses
It is used as an inhaled aerosol to treat asthma. Although it activates all beta adrenergic receptors, it works in a similar fashion to the more selective beta2-adrenergic receptor agonists e.g. salbutamol, by relaxing the airways to increase airflow.
It is also supplied in ampules under the brand name Isuprel® for injection and in sublingual pill form for treatment of asthma, chronic bronchitis and emphysema.
Used with caution, it can also be used to treat torsades de pointes, in conjunction with overdrive pacing and magnesium.
Pharmacology
Isoproterenol is a β1- and β2-adrenoceptor agonist which was commonly used to treat asthma before the more widespread use of salbutamol, which has more selective effects on the airways. Its route of administration is either intravenous, oral, intranasal, subcutaneous, or intramuscular, depending on use. The plasma half-life for isoproterenol is approximately two hours.
Isoproterenol's effects on the cardiovascular system relate to its actions on cardiac β1 receptors and β2 receptors on skeletal muscle arterioles. Isoproterenol has positive inotropic and chronotropic effects on the heart. In skeletal muscle arterioles it produces vasodilatation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure.
The adverse effects of isoproterenol are also related to the drug's cardiovascular effects. Isoproterenol can produce an elevated heart rate (tachycardia), which predisposes patients to cardiac dysrhythmias.
Warnings and Contraindications
Isoproterenol should not be administered to patients with myocardial ischaemia.
Cardiac stimulants excluding cardiac glycosides (C01C) | |
|---|---|
| Adrenergic and dopaminergic agents | Etilefrine • Isoprenaline • Norepinephrine • Dopamine • Norfenefrine • Phenylephrine • Dobutamine • Oxedrine • Metaraminol • Methoxamine • Mephentermine • Dimetofrine • Prenalterol • Dopexamine • Gepefrine • Ibopamine • Midodrine • Octopamine • Fenoldopam • Cafedrine • Arbutamine • Theodrenaline • Epinephrine |
| Phosphodiesterase inhibitors (PDE3I) | Amrinone • Milrinone • Enoximone • Bucladesine |
| Other cardiac stimulants | Angiotensinamide • Xamoterol • Levosimendan |
Drugs for obstructive airway diseases: asthma/COPD (R03) | |
|---|---|
| Adrenergics, inhalants | Short acting β2-agonists: Salbutamol/Levosalbutamol • Fenoterol • Terbutaline • Pirbuterol • Procaterol • Bitolterol • Rimiterol • Carbuterol • Tulobuterol • Reproterol Long acting β2-agonists (LABA): Arformoterol • Bambuterol • Clenbuterol • Formoterol • Salmeterol Ultra LABA: Indacaterol other: Epinephrine • Hexoprenaline • Isoprenaline (Isoproterenol) • Orciprenaline (Metaproterenol) |
| Glucocorticoids | Beclometasone • Budesonide • Ciclesonide • Fluticasone • Mometasone |
| Anticholinergics | Ipratropium • Tiotropium |
| Mast cell stabilizers | Cromoglicate • Nedocromil |
| Xanthines | Aminophylline • Theobromine • Theophylline |
| Leukotriene antagonists | Montelukast • Pranlukast • Zafirlukast |
| Lipoxygenase inhibitor | Zileuton |
| Thromboxane receptor antagonists | Ramatroban • Seratrodast |
| Combination products | Budesonide/formoterol • Fluticasone/salmeterol • Ipratropium/salbutamol |
ja:イソプロテレノール fr:Isoproterenol it:Isoprotenerolosk:Izoprenalín
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
